NSG 533 Exam 2 — Advanced Pharmacology (2026/2027) Wilkes University
NSG533 / NSG 533 EXAM 2 (LATEST UPDATE):
ADVANCED PHARMACOLOGY
Complete Guide with Questions and Verified Answers | 100% Correct — Wilkes
Aligned with the Wilkes University NSG 533 Course Syllabus, AACN Essentials of Master’s Education, and Advanced Pharmacology
Competencies (2026/2027 Edition).
Directions: This comprehensive examination contains 120 multiple-choice questions across 8 sections. Each question has four
options (A–D) with exactly one correct answer. The cognitive distribution is approximately 20% recall, 50% application, and
30% analysis. Approximately 75% of questions are scenario-based, reflecting advanced pharmacology clinical reasoning.
Rationales for each answer are provided and incorporate NSG 533 curriculum content, AACN Essentials, and advanced
pharmacology principles.
Section 1: Pharmacokinetics & Pharmacodynamics
Questions 1–15 (15 questions)
Q1: A 68-year-old patient receives an oral dose of a drug with a first-pass extraction ratio of 0.7. If 100 mg is
administered orally, approximately how much active drug reaches systemic circulation, and what is the
clinical implication for dosing?
A. 70 mg reaches systemic circulation; oral and IV doses are bioequivalent
B. 30 mg reaches systemic circulation; oral dose must be higher than IV dose to achieve equivalent effect
[CORRECT]
C. 100 mg reaches systemic circulation; first-pass effect is negligible for oral dosing
D. 10 mg reaches systemic circulation; the drug must be given parenterally only
Correct Answer: B
Rationale: A first-pass extraction ratio of 0.7 means 70% of the drug is metabolized on first pass through the liver, leaving
30 mg bioavailable. Per NSG 533 pharmacokinetic principles, drugs with high first-pass extraction require substantially
higher oral doses than IV doses to achieve equivalent systemic concentrations. Option A inverts the calculation, C ignores
first-pass metabolism, and D overstates the extraction effect.
Q2: A patient on a medication with a half-life of 12 hours is started on a maintenance dose without a loading
dose. Applying steady-state pharmacokinetics, approximately how long will it take to reach 94% of
steady-state concentration?
A. 12 hours
B. 24 hours
C. 36 hours
D. 48 hours [CORRECT]
Correct Answer: D
Rationale: It takes approximately 4 half-lives to reach 94% of steady state (≈94% = 1 - (1/2)^4). With a half-life of 12
hours, 4 half-lives = 48 hours. NSG 533 curriculum emphasizes this principle for determining when therapeutic drug
monitoring becomes meaningful. Options A and B reflect 1-2 half-lives (50-75% steady state), and C reflects 3 half-lives
(87.5%).
Complete Guide with Verified Answers Page 1 100% Correct
,NSG 533 Exam 2 — Advanced Pharmacology (2026/2027) Wilkes University
Q3: A patient weighing 80 kg is prescribed a drug with a volume of distribution (Vd) of 0.6 L/kg and a desired
steady-state plasma concentration of 10 mg/L. Using the loading dose formula (LD = Css × Vd), what is the
appropriate loading dose?
A. 240 mg
B. 480 mg [CORRECT]
C. 600 mg
D. 800 mg
Correct Answer: B
Rationale: Total Vd = 0.6 L/kg × 80 kg = 48 L. Loading dose = Css × Vd = 10 mg/L × 48 L = 480 mg. NSG 533
pharmacokinetic calculations require weight-based Vd adjustments. Option A omits weight, C miscalculates Vd as 60 L,
and D uses an incorrect Vd value.
Q4: A drug has a therapeutic index of 4 and a narrow margin of safety. Which statement best describes the
clinical significance of this finding for the advanced practice nurse?
A. The drug has a wide safety margin; routine monitoring is unnecessary
B. The toxic dose is only 4 times the therapeutic dose; close therapeutic drug monitoring is essential
[CORRECT]
C. The drug can be safely titrated rapidly without monitoring serum levels
D. The drug is contraindicated in elderly patients regardless of organ function
Correct Answer: B
Rationale: A therapeutic index of 4 indicates the toxic dose is only four-fold greater than the therapeutic dose, classifying
this as a narrow-therapeutic-index drug (e.g., digoxin, warfarin, lithium). Per AACN Essentials and NSG 533 principles,
such drugs require serum drug monitoring, individualized dosing, and careful assessment for signs of toxicity. Options A
and C contradict the principle of narrow therapeutic indices, and D is an overgeneralization.
Q5: A 55-year-old patient with hepatic cirrhosis is prescribed a drug that is 95% protein-bound and
metabolized primarily by the liver. The patient's serum albumin is 2.0 g/dL (normal 3.5-5.0). What is the most
important pharmacokinetic consideration when dosing this medication?
A. Increase the dose to compensate for reduced protein binding
B. Decrease the dose because free drug concentration will be elevated due to hypoalbuminemia [CORRECT]
C. Maintain the standard dose; protein binding does not affect drug efficacy
D. Switch to IV administration to bypass protein binding issues
Correct Answer: B
Rationale: Hypoalbuminemia reduces the number of protein binding sites, increasing the free (active) fraction of highly
protein-bound drugs. In hepatic impairment with reduced metabolism, the active drug accumulates, increasing toxicity
risk. NSG 533 principles require dose reduction and monitoring of free drug levels or clinical effects. Option A would
worsen toxicity, C ignores pharmacokinetic principles, and D does not address protein binding.
Complete Guide with Verified Answers Page 2 100% Correct
,NSG 533 Exam 2 — Advanced Pharmacology (2026/2027) Wilkes University
Q6: A patient is taking two medications: Drug A, a highly protein-bound medication (95%), and Drug B,
which competes for the same binding sites with higher affinity. What pharmacodynamic consequence is most
likely when Drug B is added?
A. Decreased therapeutic effect of Drug A due to enhanced metabolism
B. Increased free Drug A concentration, potentially causing toxicity [CORRECT]
C. Decreased absorption of Drug A from the GI tract
D. Increased renal clearance of Drug A, requiring dose escalation
Correct Answer: B
Rationale: Displacement from protein binding sites by a competitor drug increases the free fraction of Drug A, potentially
causing enhanced pharmacologic effects and toxicity. NSG 533 emphasizes that this interaction is most clinically
significant for highly protein-bound drugs with narrow therapeutic indices (e.g., warfarin displaced by sulfonamides).
Option A misattributes the mechanism to metabolism, C confuses displacement with absorption, and D misinterprets renal
effects.
Q7: A drug demonstrates a dose-response curve where doubling the dose increases effect by only 15% beyond
the maximum effect plateau. This pharmacodynamic property is best described as:
A. Potency
B. Efficacy [CORRECT]
C. Affinity
D. Therapeutic index
Correct Answer: B
Rationale: Efficacy (Emax) refers to the maximum effect a drug can produce, which is reflected by the plateau of the
dose-response curve. Once the maximum effect is reached, increasing the dose produces minimal additional benefit. NSG
533 pharmacodynamic principles distinguish potency (EC50) from efficacy (Emax). Option A refers to the dose needed for
50% effect, C describes receptor binding, and D is the safety margin ratio.
Q8: A patient receives an antagonist that binds to the same receptor as the endogenous ligand but produces no
intrinsic activity. After equilibrium, the antagonist is displaced by a high concentration of agonist. This
pharmacodynamic interaction is best characterized as:
A. Noncompetitive antagonism with irreversible binding
B. Competitive antagonism producing a parallel rightward shift of the dose-response curve [CORRECT]
C. Inverse agonism with negative intrinsic activity
D. Partial agonism with submaximal effect
Correct Answer: B
Rationale: Competitive antagonists bind reversibly to the same receptor site as the agonist and can be displaced by
increasing agonist concentration, producing a parallel rightward shift of the dose-response curve without reducing Emax.
NSG 533 pharmacodynamic principles distinguish this from noncompetitive antagonism (option A), which reduces Emax
and cannot be overcome by more agonist. Options C and D describe different receptor interactions.
Complete Guide with Verified Answers Page 3 100% Correct
, NSG 533 Exam 2 — Advanced Pharmacology (2026/2027) Wilkes University
Q9: A patient develops tachyphylaxis after repeated dosing of a sympathomimetic agent within 24 hours.
Which mechanism best explains this acute reduction in drug response?
A. Increased hepatic enzyme induction causing accelerated metabolism
B. Receptor downregulation and depletion of endogenous neurotransmitter stores [CORRECT]
C. Development of pharmacogenomic polymorphisms during therapy
D. Increased renal tubular secretion reducing plasma half-life
Correct Answer: B
Rationale: Tachyphylaxis is an acute, rapid decrease in drug response typically caused by receptor downregulation or
depletion of neurotransmitter stores (e.g., norepinephrine depletion with ephedra or indirect-acting sympathomimetics).
NSG 533 differentiates this from tolerance, which develops over days to weeks. Option A describes enzyme induction
(slower), C is implausible acutely, and D would change plasma concentration rather than receptor response.
Q10: An 82-year-old patient is prescribed diazepam for anxiety. Compared to a 40-year-old, which
pharmacokinetic change is most likely to prolong drug effect and increase fall risk?
A. Increased total body water and decreased fat stores
B. Decreased hepatic mass and increased body fat percentage prolonging half-life [CORRECT]
C. Increased glomerular filtration rate accelerating elimination
D. Enhanced first-pass metabolism reducing bioavailability
Correct Answer: B
Rationale: Aging reduces hepatic mass and blood flow (decreasing metabolism) while increasing body fat percentage,
prolonging the half-life of lipophilic drugs like diazepam (half-life can extend from 20 hours to 80-100 hours in elderly).
NSG 533 geriatric pharmacology principles emphasize avoiding long-acting benzodiazepines in older adults. Options A
and C describe changes opposite to aging, and D contradicts reduced hepatic function.
Q11: A drug undergoes zero-order elimination kinetics. Which pharmacokinetic principle accurately
describes this process and its dosing implications?
A. A constant fraction of the drug is eliminated per unit time; half-life is constant regardless of dose
B. A constant amount of drug is eliminated per unit time; half-life increases with higher doses [CORRECT]
C. Doubling the dose doubles the steady-state concentration proportionally
D. Therapeutic drug monitoring is unnecessary due to predictable kinetics
Correct Answer: B
Rationale: In zero-order kinetics (e.g., phenytoin, ethanol, high-dose aspirin), a constant amount of drug is eliminated per
unit time because metabolic pathways become saturated. Half-life is dose-dependent and increases with higher
concentrations. NSG 533 requires careful monitoring because small dose increases can cause disproportionate increases
in serum levels. Options A and C describe first-order kinetics, and D is incorrect given the unpredictable nature of
zero-order elimination.
Complete Guide with Verified Answers Page 4 100% Correct
NSG533 / NSG 533 EXAM 2 (LATEST UPDATE):
ADVANCED PHARMACOLOGY
Complete Guide with Questions and Verified Answers | 100% Correct — Wilkes
Aligned with the Wilkes University NSG 533 Course Syllabus, AACN Essentials of Master’s Education, and Advanced Pharmacology
Competencies (2026/2027 Edition).
Directions: This comprehensive examination contains 120 multiple-choice questions across 8 sections. Each question has four
options (A–D) with exactly one correct answer. The cognitive distribution is approximately 20% recall, 50% application, and
30% analysis. Approximately 75% of questions are scenario-based, reflecting advanced pharmacology clinical reasoning.
Rationales for each answer are provided and incorporate NSG 533 curriculum content, AACN Essentials, and advanced
pharmacology principles.
Section 1: Pharmacokinetics & Pharmacodynamics
Questions 1–15 (15 questions)
Q1: A 68-year-old patient receives an oral dose of a drug with a first-pass extraction ratio of 0.7. If 100 mg is
administered orally, approximately how much active drug reaches systemic circulation, and what is the
clinical implication for dosing?
A. 70 mg reaches systemic circulation; oral and IV doses are bioequivalent
B. 30 mg reaches systemic circulation; oral dose must be higher than IV dose to achieve equivalent effect
[CORRECT]
C. 100 mg reaches systemic circulation; first-pass effect is negligible for oral dosing
D. 10 mg reaches systemic circulation; the drug must be given parenterally only
Correct Answer: B
Rationale: A first-pass extraction ratio of 0.7 means 70% of the drug is metabolized on first pass through the liver, leaving
30 mg bioavailable. Per NSG 533 pharmacokinetic principles, drugs with high first-pass extraction require substantially
higher oral doses than IV doses to achieve equivalent systemic concentrations. Option A inverts the calculation, C ignores
first-pass metabolism, and D overstates the extraction effect.
Q2: A patient on a medication with a half-life of 12 hours is started on a maintenance dose without a loading
dose. Applying steady-state pharmacokinetics, approximately how long will it take to reach 94% of
steady-state concentration?
A. 12 hours
B. 24 hours
C. 36 hours
D. 48 hours [CORRECT]
Correct Answer: D
Rationale: It takes approximately 4 half-lives to reach 94% of steady state (≈94% = 1 - (1/2)^4). With a half-life of 12
hours, 4 half-lives = 48 hours. NSG 533 curriculum emphasizes this principle for determining when therapeutic drug
monitoring becomes meaningful. Options A and B reflect 1-2 half-lives (50-75% steady state), and C reflects 3 half-lives
(87.5%).
Complete Guide with Verified Answers Page 1 100% Correct
,NSG 533 Exam 2 — Advanced Pharmacology (2026/2027) Wilkes University
Q3: A patient weighing 80 kg is prescribed a drug with a volume of distribution (Vd) of 0.6 L/kg and a desired
steady-state plasma concentration of 10 mg/L. Using the loading dose formula (LD = Css × Vd), what is the
appropriate loading dose?
A. 240 mg
B. 480 mg [CORRECT]
C. 600 mg
D. 800 mg
Correct Answer: B
Rationale: Total Vd = 0.6 L/kg × 80 kg = 48 L. Loading dose = Css × Vd = 10 mg/L × 48 L = 480 mg. NSG 533
pharmacokinetic calculations require weight-based Vd adjustments. Option A omits weight, C miscalculates Vd as 60 L,
and D uses an incorrect Vd value.
Q4: A drug has a therapeutic index of 4 and a narrow margin of safety. Which statement best describes the
clinical significance of this finding for the advanced practice nurse?
A. The drug has a wide safety margin; routine monitoring is unnecessary
B. The toxic dose is only 4 times the therapeutic dose; close therapeutic drug monitoring is essential
[CORRECT]
C. The drug can be safely titrated rapidly without monitoring serum levels
D. The drug is contraindicated in elderly patients regardless of organ function
Correct Answer: B
Rationale: A therapeutic index of 4 indicates the toxic dose is only four-fold greater than the therapeutic dose, classifying
this as a narrow-therapeutic-index drug (e.g., digoxin, warfarin, lithium). Per AACN Essentials and NSG 533 principles,
such drugs require serum drug monitoring, individualized dosing, and careful assessment for signs of toxicity. Options A
and C contradict the principle of narrow therapeutic indices, and D is an overgeneralization.
Q5: A 55-year-old patient with hepatic cirrhosis is prescribed a drug that is 95% protein-bound and
metabolized primarily by the liver. The patient's serum albumin is 2.0 g/dL (normal 3.5-5.0). What is the most
important pharmacokinetic consideration when dosing this medication?
A. Increase the dose to compensate for reduced protein binding
B. Decrease the dose because free drug concentration will be elevated due to hypoalbuminemia [CORRECT]
C. Maintain the standard dose; protein binding does not affect drug efficacy
D. Switch to IV administration to bypass protein binding issues
Correct Answer: B
Rationale: Hypoalbuminemia reduces the number of protein binding sites, increasing the free (active) fraction of highly
protein-bound drugs. In hepatic impairment with reduced metabolism, the active drug accumulates, increasing toxicity
risk. NSG 533 principles require dose reduction and monitoring of free drug levels or clinical effects. Option A would
worsen toxicity, C ignores pharmacokinetic principles, and D does not address protein binding.
Complete Guide with Verified Answers Page 2 100% Correct
,NSG 533 Exam 2 — Advanced Pharmacology (2026/2027) Wilkes University
Q6: A patient is taking two medications: Drug A, a highly protein-bound medication (95%), and Drug B,
which competes for the same binding sites with higher affinity. What pharmacodynamic consequence is most
likely when Drug B is added?
A. Decreased therapeutic effect of Drug A due to enhanced metabolism
B. Increased free Drug A concentration, potentially causing toxicity [CORRECT]
C. Decreased absorption of Drug A from the GI tract
D. Increased renal clearance of Drug A, requiring dose escalation
Correct Answer: B
Rationale: Displacement from protein binding sites by a competitor drug increases the free fraction of Drug A, potentially
causing enhanced pharmacologic effects and toxicity. NSG 533 emphasizes that this interaction is most clinically
significant for highly protein-bound drugs with narrow therapeutic indices (e.g., warfarin displaced by sulfonamides).
Option A misattributes the mechanism to metabolism, C confuses displacement with absorption, and D misinterprets renal
effects.
Q7: A drug demonstrates a dose-response curve where doubling the dose increases effect by only 15% beyond
the maximum effect plateau. This pharmacodynamic property is best described as:
A. Potency
B. Efficacy [CORRECT]
C. Affinity
D. Therapeutic index
Correct Answer: B
Rationale: Efficacy (Emax) refers to the maximum effect a drug can produce, which is reflected by the plateau of the
dose-response curve. Once the maximum effect is reached, increasing the dose produces minimal additional benefit. NSG
533 pharmacodynamic principles distinguish potency (EC50) from efficacy (Emax). Option A refers to the dose needed for
50% effect, C describes receptor binding, and D is the safety margin ratio.
Q8: A patient receives an antagonist that binds to the same receptor as the endogenous ligand but produces no
intrinsic activity. After equilibrium, the antagonist is displaced by a high concentration of agonist. This
pharmacodynamic interaction is best characterized as:
A. Noncompetitive antagonism with irreversible binding
B. Competitive antagonism producing a parallel rightward shift of the dose-response curve [CORRECT]
C. Inverse agonism with negative intrinsic activity
D. Partial agonism with submaximal effect
Correct Answer: B
Rationale: Competitive antagonists bind reversibly to the same receptor site as the agonist and can be displaced by
increasing agonist concentration, producing a parallel rightward shift of the dose-response curve without reducing Emax.
NSG 533 pharmacodynamic principles distinguish this from noncompetitive antagonism (option A), which reduces Emax
and cannot be overcome by more agonist. Options C and D describe different receptor interactions.
Complete Guide with Verified Answers Page 3 100% Correct
, NSG 533 Exam 2 — Advanced Pharmacology (2026/2027) Wilkes University
Q9: A patient develops tachyphylaxis after repeated dosing of a sympathomimetic agent within 24 hours.
Which mechanism best explains this acute reduction in drug response?
A. Increased hepatic enzyme induction causing accelerated metabolism
B. Receptor downregulation and depletion of endogenous neurotransmitter stores [CORRECT]
C. Development of pharmacogenomic polymorphisms during therapy
D. Increased renal tubular secretion reducing plasma half-life
Correct Answer: B
Rationale: Tachyphylaxis is an acute, rapid decrease in drug response typically caused by receptor downregulation or
depletion of neurotransmitter stores (e.g., norepinephrine depletion with ephedra or indirect-acting sympathomimetics).
NSG 533 differentiates this from tolerance, which develops over days to weeks. Option A describes enzyme induction
(slower), C is implausible acutely, and D would change plasma concentration rather than receptor response.
Q10: An 82-year-old patient is prescribed diazepam for anxiety. Compared to a 40-year-old, which
pharmacokinetic change is most likely to prolong drug effect and increase fall risk?
A. Increased total body water and decreased fat stores
B. Decreased hepatic mass and increased body fat percentage prolonging half-life [CORRECT]
C. Increased glomerular filtration rate accelerating elimination
D. Enhanced first-pass metabolism reducing bioavailability
Correct Answer: B
Rationale: Aging reduces hepatic mass and blood flow (decreasing metabolism) while increasing body fat percentage,
prolonging the half-life of lipophilic drugs like diazepam (half-life can extend from 20 hours to 80-100 hours in elderly).
NSG 533 geriatric pharmacology principles emphasize avoiding long-acting benzodiazepines in older adults. Options A
and C describe changes opposite to aging, and D contradicts reduced hepatic function.
Q11: A drug undergoes zero-order elimination kinetics. Which pharmacokinetic principle accurately
describes this process and its dosing implications?
A. A constant fraction of the drug is eliminated per unit time; half-life is constant regardless of dose
B. A constant amount of drug is eliminated per unit time; half-life increases with higher doses [CORRECT]
C. Doubling the dose doubles the steady-state concentration proportionally
D. Therapeutic drug monitoring is unnecessary due to predictable kinetics
Correct Answer: B
Rationale: In zero-order kinetics (e.g., phenytoin, ethanol, high-dose aspirin), a constant amount of drug is eliminated per
unit time because metabolic pathways become saturated. Half-life is dose-dependent and increases with higher
concentrations. NSG 533 requires careful monitoring because small dose increases can cause disproportionate increases
in serum levels. Options A and C describe first-order kinetics, and D is incorrect given the unpredictable nature of
zero-order elimination.
Complete Guide with Verified Answers Page 4 100% Correct
